Progenics Pharmaceuticals Inc (PGNX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9946)
◆英語タイトル:Progenics Pharmaceuticals Inc (PGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9946
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Progenics Pharmaceuticals Inc (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company’s pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product EXINI Bone BSI tool and is approved for use in Europe, Japan and the US. The company markets Relistor, through a licensing agreement with Salix Pharmaceuticals outside the US except Japan. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc (PGNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 12
Exini Diagnostics Enters into Agreement with DexTech Medical for OsteoDex 13
Licensing Agreements 14
Progenics Pharma Enters into Licensing Agreement with Selexis 14
Bayer Enters into Licensing Agreement with Progenics Pharma 15
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 16
Molecular Insight Pharma Enters into Licensing Agreement with University of Zurich and Paul Scherrer Institute 17
ITM Isotopen Enters Into Licensing Agreement With Progenics Pharma For Dotatoc 18
Equity Offering 19
Progenics Pharma Plans to Raise up to USD75 Million in Public Offering of Shares 19
Progenics Pharma Prices Public Offering of Shares for USD75 Million 20
Progenics Pharma Completes Public Offering Of Shares For US$35 Million 22
Progenics Pharma Completes Public Offering Of Shares For US$37 Million 23
Progenics Pharma Completes Public Offering Of Common Stock For US$25 Million 24
Asset Transactions 26
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 26
Acquisition 28
Progenics Pharma Acquires Molecular Insight Pharma for up to USD106 Million 28
Progenics Pharmaceuticals Inc – Key Competitors 30
Progenics Pharmaceuticals Inc – Key Employees 31
Progenics Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Jul 31, 2018: Azedra’s approval, progenics pharmaceuticals announces second quarter 2018 financial results and business update 33
May 09, 2018: Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update 36
Mar 08, 2018: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update 38
Nov 02, 2017: Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update 40
Aug 09, 2017: Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update 42
May 04, 2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update 44
Mar 09, 2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update 46
Clinical Trials 48
Dec 06, 2017: First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin) 48
Nov 14, 2017: Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin) in Cancer Patients with GEP-NET 50
Feb 14, 2017: Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 12
Exini Diagnostics Enters into Agreement with DexTech Medical for OsteoDex 13
Progenics Pharma Enters into Licensing Agreement with Selexis 14
Bayer Enters into Licensing Agreement with Progenics Pharma 15
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 16
Molecular Insight Pharma Enters into Licensing Agreement with University of Zurich and Paul Scherrer Institute 17
ITM Isotopen Enters Into Licensing Agreement With Progenics Pharma For Dotatoc 18
Progenics Pharma Plans to Raise up to USD75 Million in Public Offering of Shares 19
Progenics Pharma Prices Public Offering of Shares for USD75 Million 20
Progenics Pharma Completes Public Offering Of Shares For US$35 Million 22
Progenics Pharma Completes Public Offering Of Shares For US$37 Million 23
Progenics Pharma Completes Public Offering Of Common Stock For US$25 Million 24
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 26
Progenics Pharma Acquires Molecular Insight Pharma for up to USD106 Million 28
Progenics Pharmaceuticals Inc, Key Competitors 30
Progenics Pharmaceuticals Inc, Key Employees 31
Progenics Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Progenics Pharmaceuticals Inc (PGNX):製薬・医療:M&Aディール及び事業提携情報(Progenics Pharmaceuticals Inc (PGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆